Dorota Krochmalczyk

Krakow, MA, Poland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV).

Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV).

Journal: HemaSphere
Published: January 28, 2025

Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera.

Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera.

Journal: Leukemia
Published: August 13, 2024

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.

Journal: Leukemia
Published: May 15, 2023

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs.

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs.

Journal: Blood advances
Published: January 31, 2022

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.

Journal: Leukemia
Published: December 25, 2021

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups.

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups.

Journal: HemaSphere
Published: April 14, 2020

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.

Journal: The Lancet. Haematology
Published: July 23, 2019

Safety and Efficacy of Bendamustine Monotherapy in the First-Line Treatment of Patients with Chronic Lymphocytic Leukemia: Polish Lymphoma Research Group Real-Life Analysis.

Safety and Efficacy of Bendamustine Monotherapy in the First-Line Treatment of Patients with Chronic Lymphocytic Leukemia: Polish Lymphoma Research Group Real-Life Analysis.

Journal: Chemotherapy
Published: April 22, 2019

Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.

Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.

Journal: Clinical lymphoma, myeloma & leukemia
Published: October 22, 2018

A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs.

A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs.

Journal: Annals of hematology
Published: May 21, 2018

Escalated BEACOPP as an alternative in high risk Hodgkin lymphoma

Escalated BEACOPP as an alternative in high risk Hodgkin lymphoma

Journal: Przeglad lekarski
Published: October 12, 2012
Showing 1-11 of 11

Last Updated: 09/26/2026